Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Monogram Biosciences has entered into a collaboration agreement with the Dana-Farber Cancer Institute to utilize Monogram's eTag technology in preclinical and clinical oncology research studies.
Subscribe to our email newsletter
The purpose of these studies will be to identify and validate clinical biomarkers and predictive algorithms for disease prognosis and therapeutic response.
Under the agreement, Monogram and Dana-Farber will jointly conduct experiments employing eTag assays to investigate the relationship between signaling pathway activation and clinical responsiveness to targeted drugs in a variety of important cancers. Monogram will have rights to diagnostic and predictive medicine applications of all resulting inventions.
“We believe that our eTag technology may open up a completely new approach to the management of serious diseases. The collaboration with the world class researchers at Dana-Farber will help us in our mission to match the right drug to the right patient at the right time,” stated William Young, CEO of Monogram.